There are 410 resources available
Q&A and closing remarks
Presenter: Enriqueta Felip
Session: Janssen Pharmaceuticals - Exploring clinical perspectives in advanced EGFR-mutant NSCLC: How far we have come
Resources:
Webcast
Oncogenic fusions: Targeting ROS1, RET and NTRK
Presenter: Misako Nagasaka
Session: Genomic alterations beyond EGFR and ALK
Resources:
Slides
Webcast
Peri-operative TKI in EGFR mutant tumours and beyond
Presenter: JORDI REMON MASIP
Session: Peri-operative strategies in early stage NSCLC with IO and targeted therapies
Resources:
Slides
Webcast
Case presentation
Presenter: Giulia Galli
Session: Stage III thymoma
Resources:
Slides
Webcast
Lights and shadows for the neoadjuvant ICI strategy
Presenter: Lizza Hendriks
Session: Peri-operative strategies in early stage NSCLC with IO and targeted therapies
Resources:
Slides
Webcast
When do we switch local to systemic and systemic to local treatment?
Presenter: Hidehito Horinouchi
Session: Stage III thymoma
Resources:
Slides
Webcast
New advances in BRAF and MET Exon 14 skipping mutations
Presenter: David Planchard
Session: Genomic alterations beyond EGFR and ALK
Resources:
Slides
Webcast
Targeting KRAS g12C mutations and beyond
Presenter: Lyudmila Bazhenova
Session: Genomic alterations beyond EGFR and ALK
Resources:
Slides
Webcast
Lights and shadows for the adjuvant ICI strategy
Presenter: Jessica Menis
Session: Peri-operative strategies in early stage NSCLC with IO and targeted therapies
Resources:
Slides
Webcast
HER2 alterations: Past, present and future
Presenter: Antonio Passaro
Session: Genomic alterations beyond EGFR and ALK
Resources:
Slides
Webcast